Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO 2015: Immunotherapy Shines

This article was originally published in Scrip

Executive Summary

Three days into the 2015 American Society of Clinical Oncology annual meeting, there have been hundreds of data presentations, but a few have stuck out. The stand-outs come from across therapeutic categories and range from the hot area of immunotherapy to already-marketed products.

BMS changes the landscape

Bristol-Myers Squibb had a variety of data presentations at the conference, but its Checkmate-057 data caused quite a stir. The company's stock sold off when the late-breaking abstract was first released on 29 May due to the overall survival benefit only being seen in PD-L1 positive patients, but the full data presentation the following day has got analysts raving about the potential of Opdivo (nivolumab) in second-line non-small cell lung cancer (NSCLC).

The Phase III study of 582 previously-treated NSCLC patients showed that Opdivo was associated with a 27% reduction in the risk of progression or death compared with standard-of-care chemotherapy docetaxel. The drug compared with chemotherapy showed the best overall survival benefit – virtually double – in patients with greater than or equal to 10% PD-L1 expression (19.4 months vs 8.0 months).

Median Overall Survival Benefit by PD-L1 Expression

 

Level of Expression

 

Opdivo

 

docetaxel

 

? 1%

 

17.2 months

 

9.0 months

 

<>

 

10.4 months

 

10.1 months

 

? 5%

 

18.2 months

 

8.1 months

 

<>

 

9.7 months

 

10.1 months

 

? 10%

 

19.4 months

 

8.0 months

 

<>

 

9.9 months

 

10.3 months

 

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel